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ABSTRACT
The epidermal growth factor receptor (EGFR), a mem-
ber of the ErbB family of receptor tyrosine kinases, 
plays an important role in the control of cell growth 
and differentiation. Disruption of its signaling leads to 
neoplastic cell proliferation, migration, stromal inva-
sion, resistance to apoptosis, and angiogenesis. 
EGFR is overexpressed in a variety of solid tu-
mors, including colorectal cancer (CRC), and its over-
expression is associated with poorer prognosis. One 
class of agents that is currently used to target EGFR in 
the treatment of metastatic CRC (mCRC) is the mono-
clonal antibodies. While the monoclonal antibody 
EGFR inhibitors lack many of the severe side effects 
commonly observed with cytotoxic chemotherapy, 
they are associated with a set of unique dermatologi-
cal toxicities. This paper reviews the safety profile of 
the anti-EGFR monoclonal antibodies cetuximab and 
panitumumab in the treatment of mCRC.
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1.  InTRODuCTIOn
The epidermal growth factor receptor (EGFR), a 
member of the ErbB family of receptor tyrosine 
kinases1,2,3, is a transmembrane glycoprotein com-
posed of an extracellular ligand-binding domain, a 
transmembrane lipophilic segment, and an intracel-
lular protein kinase domain4.
EGFR is activated by EGF-like ligands, includ-
ing EGF, transforming growth factor alpha (TGF-α), 
amphiregulin, heparin-binding EGF-like growth fac-
tor, betacellulin, and epiregulin5. Binding of these 
ligands results in EGFR dimerization, which leads to 
high-affinity ligand binding, activation of the intrinsic 
protein tyrosine kinase (TK) activity, and tyrosine 
autophosphorylation. Activation of the intracellular 
protein TK leads to recruitment and phosphorylation 
of several intracellular substrates, triggering a variety 
of cellular responses including cell division, survival, 
motility, invasion, adhesion, and cellular repair6,7. 
EGFR therefore plays an important role in the control 
of cell growth and differentiation8, and disruption 
of its signaling leads to neoplastic cell proliferation, 
migration, stromal invasion, resistance to apoptosis, 
and angiogenesis9. 
EGFR is overexpressed in a variety of solid tu-
mors, including colorectal cancer (CRC), squamous 
cell cancer of the head and neck, and non-small-cell 
lung cancer. EGFR overexpression is associated 
with poorer prognosis in these malignancies10-14 
and, in CRC, may be associated with an advanced 
disease stage15-18.
One class of agents that is currently used to target 
EGFR in the treatment of metastatic CRC (mCRC) is 
the monoclonal antibodies (MoAbs), which compete 
with endogenous ligands, including EGF and TGF-α 
to block ligand-dependant activation of EGFR, and 
induce receptor internalization and consequent down-
regulation19. This paper reviews the safety profile of 
the anti-EGFR MoAbs cetuximab and panitumumab 
in the treatment of mCRC.
2.  DERMATOlOGICAl TOxICITIES
While the MoAb EGFR inhibitors lack many of the 
severe side effects commonly observed with cyto-
toxic chemotherapy, they are associated with a set 
of unique dermatological toxicities. The majority of 
patients treated with a MoAb EGFR inhibitor will 
experience dermatological side effects, most notably 
the papulopustular skin rash, which can impact quality 
of life and affect adherence to therapy20.
EGFR is expressed in the basal layer of the epi-
dermis and contributes to the stimulation of epidermal 
growth, inhibition of differentiation, and accelera-
tion of wound healing. Inhibition of EGFR results 
in impaired growth and migration of keratinocytes, 
and inflammatory chemokine expression by these 
cells. The resulting inflammatory cell recruitment 
and subsequent cutaneous injury account for the 
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majority of dermatological symptoms associated 
with anti-EGFR therapy including papulopustular 
eruption, hair growth disorders, periungual and nail 
plate abnormalities, xerosis, telangiectasias, and 
pruritus13,21-29. Disruptions to this barrier may also 
promote bacterial overgrowth30, further exacerbating 
injury to the cutaneous tissue.
Skin toxicities have been reported in 80–95% of 
patients with mCRC treated with cetuximab and pani-
tumumab monotherapy (Tables 1, 2)31, with a similar 
frequency seen in trials of cetuximab in combination 
with chemotherapy (Table 3). The most severe skin 
toxicities (grades 3-4) have been seen in trials com-
bining bevacizumab with the EGFR inhibitors32-34. 
Ta b l e  I.  AEs in cetuximab monotherapy trials31
Saltz et al.  
(2004)
Cunningham et al. 
(2004)
Lenz et al.  
(2006)
Jonker et al.  
(2007)
Wierzbicki et al.  
(2008)
n of patients 57 115 346 287 85
Any AE, n (%)  NR  50 (43.5)  NR  226 (78.5)  81 (95.3) 
Any skin toxicity (%) 88 80 82.9 88.6 NR
Phase  II  II/III  II  III  II 
Grade 3/4  AEs, %  Acne, 16; asthenia, 
4; atrial fibrillation, 
2; hypokalemia, 2; 
rash, 2; vomiting, 
2; confusion, 
2; diarrhea, 2; 
headache, 2 
Dyspnea, 13.0; 
asthenia, 10.4; 
acne-like rash, 5.2; 
abdominal pain, 5.2; 
nausea/vomiting, 
4.3; anemia, 2.6; 
diarrhea, 1.7; 
thrombocytopenia, 
0.9; stomatitis, 0.9 
Acne, 4.9; 
asthenia, 2.0; 
headache, 1.2; 
diarrhea, 1.2; 
nausea, 0.6; dry 
skin, 0.6; fever, 
0.3 
Fatigue, 33.0; dyspnea, 
16.3; abdominal pain, 13.2; 
pain–other, 14.9; infection 
without neutropenia, 12.8: 
rash or desquamation, 11.8; 
hypomagnesemia, 5.8; 
edema, 5.2; anorexia, 8.3; 
constipation, 3.5; nausea, 5.6; 
vomiting, 5.6; confusion, 5.6 
Dermatitis, 4.7; 
hypomagnesemia, 
4.7; dyspnea 2.4; 
headache, 1.2 
Onset of skin toxicity  1–3 wks  1–3 wks  8–19 days  NR  NR 
Infusion reactions, 
type, n (%) n of 
patients 
Allergic reactions, 
3 (5) 
Hypersensitivity 
reaction, 4 (3.5) 
Hypersensitivity 
reaction, 26 (7.5) 
Hypersensitivity reaction, 
13 (4.5) 
Infusion reaction 
grade ≥3, (3.5) 
Ta b l e  II. AEs in panitumumab monotherapy trials31
Van Cutsem et al.  
(2007) 
Van Cutsem et 
al. (2008)  Berlin et al. (2006)  Hecht et al.  
(2008) 
Hecht et al.  
(2007) 
229 176 93 203 148
Any AE, n (%)  79 (35)  32 (18)  23 (25)  88 (42)  18 (12) 
Any skin toxicity (%) 90% NR 96 NR 95
Phase  III  II  II  II  II 
Grade 3/4 AE, %  Acneiform rash, 7.4; 
abdominal pain, 7.4; 
erythema, 5.2; dyspnea, 4.8; 
fatigue, 4.4; anorexia, 3.5; 
asthenia, 3.1; constipation, 
2.6; pruritus, 2.2; skin 
exfoliation, 2.2; vomiting, 
2.2; hypomagnesemia, 3.0; 
back pain, 1.7; paronychia, 
1.3; diarrhea, 1.3; nausea, 
0.9; rash, 0.9; skin fissures, 
0.9; edema, 0.9; cough 0.4 
Acne, 6.2; 
erythema, 
5.1; rash, 4.5; 
other skin 
manifestations, 
2.3; paronychia, 
1.7; pruritus, 
1.1; skin 
exfoliation, 0.6; 
diarrhea, 0.6; 
conjunctivitis, 
0.6 
Acneiform rash, 
9.9; erythema, 6.6; 
rash, 3.3; pruritus, 
2.2; paronychia, 
2.2; hypokalemia, 
2.2; exfoliation, 
1.1; skin fissures, 
1.1; vomiting, 
1.1; anorexia, 1.1; 
hypomagnesemia, 1.1 
Acneiform rash, 6; 
erythema, 5; pruritus, 
3; rash, 3; exfoliation, 
3; nausea/vomiting, 
2; fatigue/asthenia, 2; 
diarrhea, 2; dyspnea, 1; 
infections, 6 
Rash, 3; fatigue, 
3; vomiting, 
1; pruritus, 
1; nausea, 1; 
diarrhea, 1; 
dyspnea, 1 
Onset of skin toxicity  12–15 days  NR  6–13 days  NR  9–14 days 
Infusion reactions, 
type, n (%) 
Infusion reaction, 0 (0); 
only one grade 2 reaction 
Moderate 
hypersensitivity, 
1 (0.6) 
Infusion reaction, 
1 (1) 
Infusion reaction, grade 
3 or 4, 7 (3) 
Hypersensitivity 
reaction, 1 (0.7) S20
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In the CAIRO2 trial, the addition of cetuximab to 
capecitabine, oxaliplatin and bevacizumab in the first-
line treatment of mCRC did not result in excessive 
toxicity33. However, an overall increase in grade 3–4 
toxicity was seen in the cetuximab arm, which was 
fully attributed to cetuximab-related skin toxicity. In 
the BOND trial, grade 3–4 skin toxicity occurred at a 
rate of 13% in the group treated with cetuximab and 
irinotecan13. In BOND2, the grade 3 skin rash was 
observed in 21% of patients treated with a combina-
tion of cetuximab, irinotecan, and bevacizumab35, 
suggesting that there is considerable worsening of 
skin toxicity with the addition of bevacizumab to an 
anti-EGRF treatment regimen.
The PACCE (Panitumumab Advanced Colorec-
tal Cancer Evaluation) study evaluated the efficacy 
and safety of adding panitumumab to combination 
chemotherapy with bevacizumab for the first-line 
treatment of mCRC34. PACCE was stopped early 
when a planned interim analysis revealed an increased 
incidence of toxicity with no improvement of in-
creased efficacy in the panitumumab arm. Grade 3-4 
skin toxicity was observed in 36% of patients treated 
with panitumumab. 
2.1  Papulopustular rash
The most common adverse event among mCRC 
patients treated with the anti-EGFR MoAbs is the 
papulopustular rash, characterized by erythematous 
inter- and intrafollicular papulopustules and com-
monly affecting sun-exposed areas of the body36 
such as the face, neck, shoulders, upper body, and 
scalp37,38. In clinical trials of cetuximab and panitu-
mumab monotherapy, papulopustular rash occurred 
in the majority of patients, but in most cases were 
mild-to-moderate in severity (Tables 1, 2).
The onset of rash is early, generally developing over 
a period of six weeks after starting treatment39. The first 
week is characterized by sensory disturbance, erythema, 
and edema, followed by papulopustular eruption during 
the second week. Crusting appears by Week 4. If treated 
successfully, the papulopustular eruptions disappear 
and make way for erythema and dry skin by Week 6. 
In some cases, the rash may improve spontaneously40, 
but may also persist26. Phase I escalation studies have 
shown the rash to be dose-dependant40-42.
Although the rash may resemble acne vulgaris, it is 
clinically and histologically different. Therefore, terms 
Ta b l e  III.  Adverse events of trials with combination cetuximab therapy in the treatment of metastatic colorectal cancer31
BOND 
(Cunningham 2004)
N=212
CRYSTAL  
(Raoul 2009)
N=87
OPUS (Bokemeyer 
ECCO 2007)
N=337
BOND2 
(Saltz 2007)
N=83
CAIRO2  
(Tol Ann Oncol 2008)
n=192
Treatment 
regimen
CET + IRI CET + IRI +5-FU CET plus 5-FU/
FA/oxaliplatin 
(FOLFOX-4)
CET + BEV 
+ IRI
n=43
CET + BEV
N=40
Capecitabine +
oxaliplatin + BEV + 
CET
Any AE 65.1 NR NR NR NR NR
Skin toxicity 80 52% (rash) NR 83 85 92
Grade 3/4 
AE, %
Anemia 4.7
Neutropenia 9.4
Thrombocytopenia 
0.5
Diarrhea 21.2
Asthenia 13.7
Acne-like rash 9.4
Nausea and 
vomiting 7.1
Abdominal pain 3.3
Stomatitis 2.4
Dyspnea 1.4
Fever 2.4
Leukopenia 21.2
Diarrhea 12
Vomiting 12
Rash 12
Acne 10
Asthenia 10
Intestinal obstruction 10
Abdominal pain 6
Mucous membrane 
disorder 6
Dyspnea 8
Atrial fibrillation 4
Deep thrombophelbitis 4
Gamma glutamyl 
transpeptidase  
increased 4
Hypokalaemia 4
Liver function test 
abnormal 4
Skin disorder 4
Thrombosis 4
Urinary tract infection 4
Weight loss 4
Neutropenia 27.6
Diarrhea 7.1
Neurotoxicity 3.5
Leukopenia 7.1
Fatigue 3.5
Skin reactions 
14.1
Infusion-related 
reactions 4.1
Skin rash 21
Paronychial 
cracking 7
Skin rash 20
Paronychial 
cracking 5
Headache 5
Acneiform skin rash 26
Nail changes 6
Dry skin 0.5
Hand–foot  
syndrome 16
Diarrhoea 23
Nausea 6
Vomiting 6
Hypertension 4
Proteinuria 0.5
Cardiac ischaemia 2
Cerebrovascular 
ischaemia 0.5
Sensory neuropathy 6
Thromboembolic event 8
Infection 5
Febrile neutropenia 0
Allergic reaction 7
Bleeding 1
Gastrointestinal 
perforation 1
Hypomagnesaemia 2S21
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that imply a similarity with acne, such as “acneiform 
rash”, “acneiform follicular rash”, “acne-like rash”, 
“maculopapular rash”, or “monomorphic pustular le-
sions”, should not be used to describe the papulopustu-
lar rash associated with anti-EGFR therapy36,37,43,44.
2.1.1  Correlation between the efficacy of EGFR inhibi-
tors and the occurrence of rash
Data from the clinical trials of cetuximab and panitu-
mumab in the treatment of mCRC suggest a positive 
correlation between the presence and severity of rash 
and survival13,32,45-49. In the first phase II open-label 
trial of cetuximab monotherapy for the treatment of re-
fractory mCRC, longer survival times were observed in 
patients who experienced a rash of any grade compared 
with patients who did not have a rash (p = 0.02)32. In 
the pivotal BOND study comparing cetuximab in com-
bination with irinotecan with cetuximab alone for the 
treatment of mCRC, patients with skin reactions had 
higher response rates than patients without skin reac-
tion (25.8% vs. 6.3% in the combination group; 13.0% 
vs. 0% in the monotherapy group; p = 0.005)13.
Similar results have been observed in phase II and 
III studies of panitumumab. In a phase II study of 148 
patients with EGFR-positive mCRC, grades 2–4 skin 
toxicity was associated with longer PFS (HR 0.67; 
95% CI 0.50 to 0.90) and OS (HR 0.72; 95% CI 0.54 
to 0.97) compared with grades 0–1 skin toxicity49. In 
the pivotal phase III, open-label trial comparing panitu-
mumab monotherapy with best supportive care for the 
treatment of mCRC, exploratory analysis revealed a 
trend toward longer progression-free survival (HR 0.62; 
95% CI 0.44–0.88) and overall survival (HR 0.59, 95% 
CI 0.42–0.85) in patients with grade 2–4 skin toxicity 
compared with patients with grade 1 skin toxicity50. 
The correlation between rash and response to 
the anti-EGFR treatment suggests that treatment 
response might be optimized by increasing the dose 
until the appearance of rash. The phase I/II EVEREST 
(Evaluation of Various Erbitux Regimens by Means 
of Skin and Tumor Biopsies) trial randomly assigned 
patients with no rash or grade I rash to treatment with 
standard-dose cetuximab (250 mg/m2/week) plus iri-
notecan or an increasing dose of cetuximab (50 mg/
m2 every two weeks until grade 2 or higher toxicity, 
tumor response, to a maximum dose of 500 mg/m2)51. 
Skin toxicity and response rates both increased with 
dose escalation. Mean PFS was 4.8 months in the 
dose-escalation group compared with 3.9 months 
in those who received standard-dose cetuximab51. 
As KRAS mutation status has been shown to be a 
predictor of tumor response to anti-EGFR treatment, 
the EVEREST trial sought to determine whether dose 
escalation would also be able to induce a response 
in patients with KRAS mutations. KRAS and skin 
toxicity were found to be independent predictors of 
outcomes. Among patients with wild-type KRAS 
tumors and grade 0–1 rash, dose escalation improved 
response rates compared with the standard-dose group 
(46.4% vs. 21.1%). However, none of the patients 
with KRAS mutations achieved a response, regard-
less of the dose51.
These results suggest that the characteristic rash 
associated with EGFR inhibitors may have potential 
as a surrogate marker of efficacy in patients with 
KRAS wild type tumors. 
2.1.2  Management of skin rash associated with cetux-
imab and panitumumab
Canadian guidelines have recently been developed 
for the prevention and management of dermatological 
toxicities associated with anti-EGFR MoAb treat-
ment52. General principles include practicing sun-
protective measures and avoidance of activities and 
products that are likely to dry the skin (e.g. long, hot 
showers; alcohol-based/perfumed products; over-the-
counter acne medications). Oatmeal baths and creams 
may provide symptomatic relief. Management should 
be individualized according to the type, severity, and 
location of the rash. Specific treatment recommenda-
tions for mild, moderate, and severe rash are outlined 
in the British Columbia Cancer Agency’s rash protocol 
for EGFR inhibitors (Fig. 1). Twice daily application 
of topical clindamycin 2% plus hydrocortisone 1% 
in a lotion base is recommended for the treatment of 
mild rash. Moderate and severe rash may require the 
addition of oral minocycline or doxycycline.
Researchers at the Memorial Sloan-Kettering 
Cancer Center evaluated the ability of topical tazaro-
tene, with or without oral minocycline, to reduce or 
prevent papulopustular rash when administered in 
conjunction with cetuximab therapy53. Forty-eight 
patients with mCRC who were about to start therapy 
with cetuximab were randomly assigned to receive 
daily treatment with oral minocycline (n = 24) or 
placebo (n = 24), and topical tazarotene on either the 
left or right side of their face. Both therapies were 
administered for eight weeks. During the first four 
weeks, minocycline treatment was associated with 
significantly fewer facial lesions and lower rates of 
severe itch compared with placebo (20% vs 50%, 
p = 0.05). By Week 8, these differences were no longer 
significant. Tazarotene application did not produce 
any clinical benefit and was, in fact, associated with 
significant irritation, resulting in its discontinuation 
in one-third of patients.
The largest randomized prospective study to 
demonstrate the efficacy of prophylactic interven-
tion in reducing the risk of skin toxicity with an 
anti-EGFR therapy was the STEPP (Skin Toxicity 
Evaluation Protocol with Panitumumab) trial.  The 
STEPP trial evaluated the differences between pre-
emptive and reactive treatments for skin toxicities 
associated with EGFR inhibition by panitumumab 
in 58 patients receiving panitumumab plus FOLFIRI 
or irinotecan-only chemotherapy for second-line 
treatment of mCRC54. Patients with mCRC who had 
previously failed treatment with oxaliplatin-based 
FAKIH et al.S22
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chemotherapy were randomly assigned to biweekly 
treatment with FOLFIRI–based chemotherapy plus 
panitumumab or treatment with irinotecan-based 
chemotherapy plus panitumumab every three 
weeks. Within each treatment group, patients were 
randomly assigned to receive skin toxicity treat-
ment 24 hours before the first panitumumab dose 
and then daily through Week 6 (preemptive) or after 
skin toxicity developed (reactive)54. Skin toxicity 
treatment included the use of skin moisturizers, 
sunscreen, 1% hydrocortisone cream, and doxy-
cycline 100 mg bid. Preemptive treatment reduced 
the incidence of grade 2 or greater skin toxicities by 
more than 50% compared with reactive treatment, 
without additional side effects. Time to severe skin 
toxicity and time to first occurrence of a grade 2 or 
greater skin toxicity were also significantly delayed 
by preemptive treatment. Prophylactic manage-
ment of skin toxicity was not associated with any 
reduction in efficacy when compared to the reactive 
skin toxicity arm.
In addition to treatment with topical and oral 
antibiotics, specific dose reductions and treatment 
delays are recommended for patients who develop 
severe rash on cetuximab (Table 4)55.
2.2  Xerosis
Xerosis, or excessive dryness of the skin, is generally 
characterized by diffuse, fine scaling. Xerosis occurs in 
up to 35% of patients treated with an EGFR inhibitor56, 
and is more common among older patients or those with 
a history of atopic eczema37. Xerosis may be compli-
cated by chronic asteototic eczema, or “winter eczema”, 
which is characterized by pruritic, dry, cracked, and 
polygonally fissured skin with irregular scaling. 
Xerosis is associated with a significant decrease 
in free fatty acids in the stratum corneum. Cutaneous 
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loss of these fatty acids increases transepidermal 
water loss, causing the cells to shrink and reducing 
the skin’s elasticity. This disruption of the epidermal 
layer can lead to inflammation and an increased risk 
of infection by Staphylococcus aureus or, less com-
monly, herpes simplex virus type I23,24. Systemic and/
or topical antibiotics may be required57. Pruritus may 
be alleviated with antihistamines39, and anecdotal 
reports suggest that pregabalin may control pruritus 
associated with cetuximab therapy58.
Painful fissures may appear on the palms, 
fingertips, soles of the feet and toes, and on the 
lips20,21,24,59,60. Fissures should be treated with emol-
lients, and sealed with cyanoacrylate or flurander-
nolide tape that delivers high-potency steroids and 
protects against mechanical trauma61.
2.3  Paronychia
Paronychia is an infection that occurs where the nail 
and skin meet at the side or the base of a fingernail or 
toenail. Occurring in 10% to 15% of patients treated 
with cetuximab and gefitinib24,26,29,62, this side effect 
generally presents four to eight weeks from the start of 
treatment with an EGFR inhibitor MoAb. Paronychia 
associated with EGFR blockade is characterized by 
an erythematous and painful inflammation of the nail 
fold, which may swell and form granulation tissue37. 
The nails may become brittle and slower growing. 
In severe cases, paronychia perungual abscess and 
pyogenic granuloma of the nail fold may develop62. 
Secondary bacterial (S. aureus) or fungal (Candida 
albicans) infection is common in paronychia associ-
ated with EGFR inhibition29,63,64.
Minocycline or doxycycline 100 mg bid and 
high-potency topical steroids may be effective in the 
treatment of paronychia61. Extreme cases may require 
nail local steroid injections or nail fulguration. 
2.4  Hair changes
Some patients who undergo treatment with an EGFR 
inhibitor may experience changes to their hair, 
most notably an increased growth of the eyelashes 
(trichomegaly)37,65,66. However, the patient’s scalp 
hair may become finer, brittle, and curly, and hyper-
trichosis of the face may develop67, suggesting that 
the mechanism regulating hair growth may differ in 
different parts of the body66. In three clinical studies 
investigating the safety and efficacy of panitumumab 
monotherapy in mCRC in a single institution, hirsut-
ism was reported in half of women who received 
panitumumab for more than six weeks68. 
Hair changes usually appear later during the 
course of treatment – two to five months after begin-
ning treatment – and generally resolve within a month 
of discontinuing treatment37.
2.5  Telangiectasias and hyperpigmentation
Telangiectasias are small dilated blood vessels that 
develop in a small proportion of patients taking EGFR 
inhibitors, generally appearing on the face, chest, 
back, and limbs. Hyperpigmentation may result from 
fading telangiectasias24,59,60 or as a consequence of 
inflammation. Because telangiectasias and hyperpig-
mentation usually occur as a result of photosensitivity, 
patients being treated with an EGFR inhibitor should 
be counseled to practice sun protection. The Canadian 
Dermatology Association has outlined sun protection 
for the general population, which includes wearing 
an SPF 30 broad-spectrum sunscreen, scheduling 
outdoor activities before 11 am and after 4 pm, and 
wearing appropriate clothing to cover the skin, includ-
ing hat. Darker-skinned individuals, in particular, are 
susceptible to hyperpigmentation24,43,59,60,68,69.
2.6  Radiation dermatitis
With the increasing use of EGFR inhibitors with or 
following radiotherapy, recent reports have indicated 
a potential for cetuximab to enhance the severity of 
radiation dermatitis70-72. The radiation oncology de-
partment of the University of Dusseldorf, Germany, 
observed two cases of unusually severe radiation 
dermatitis among a small group of five patients with 
Ta b l e  IV.  Grades 3 and 4 events in the STEPP trial20
Pmab + FOLFIRI 
Q2W
Pmab + Iri Q3W Pmab + FOLFIRI Q2W Pmab + Iri
Q3W
KRAS
P (n=28) R (n=27) P (n=20) R (n=20) WT KRAS 
(n=32)
Mut KRAS 
(n=19)
WT  KRAS 
(n=17)
Mut KRAS 
(n=19)
Dermatitis acneiform - n (%)  2 (7) 7 (26) 0 (0) 3 (15) 7 (22) 2 (11) 1 (6) 2 (11)
Diarrhea - n (%)  6 (21) 9 (33) 1 (5) 6 (30) 10 (31) 4 (21) 2 (12) 4 (21)
Dehydration - n (%)  3 (11) 7 (26) 0 (0) 6 (30) 5 (16) 4 (21) 1 (6) 4 (21)
Neutropenia - n (%)  3 (11) 7 (26) 1 (5) 5 (25) 5 (16) 3 (16) 3 (18) 3 (16)
Deep vein thrombosis – n (%)  0 (0) 1 (4) 0 (0) 1 (5) 1 (3) 0 (0) 0 (0) 0 (0)S24
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head and neck cancer (HNC) treated with irradiation 
and concurrent cetuximab71. The appearance of these 
cases prompted the researchers to conduct a survey 
of members of the EORTC Head and Neck Radiation 
Oncology Group. Among 71 HNC patients from 15 
institutions who had been treated with cetuximab and 
concurrent radiotherapy and for whom information 
on dermatological reactions was available, 15 and 
20 patients developed grade 3 and grade 4 radiation 
dermatitis (49%), respectively73. In another recent 
report of 13 consecutive patients with HNC treated 
with concurrent cetuximab and radiotherapy, 10 
(77%) experienced severe skin reactions (grade 3–4), 
which were associated with low treatment compliance 
and delays in completing RT74.
These results are in contradiction to results of 
a large, multinational, randomized study, where the 
concurrent addition of cetuximab to radiation treat-
ment did not increase the rate of grade 3-4 radiation 
dermatitis (11% cetuximab plus radiotherapy vs 8.5% 
radiotherapy alone; p = 0.27)75. A potential reason for 
this discrepancy in the German study is selection bias, 
as institutions that had observed cases of severe radia-
tion dermatitis may have been more likely to respond 
to the survey than those who had not. As well, the total 
number of patients might have been underestimated 
due to the lack of formal registry of cetuximab pa-
tients in most institutions. Another potential reason 
for the increase in radiation dermatitis observed in 
the more recent studies is the removal of radiation 
dermatitis as a dose-limiting toxicity of radiotherapy, 
since the introduction of megavoltage radiotherapy. 
As a result, severe radiation dermatitis may have been 
underreported in the earlier trial71,73.
3.  OCulAR TOxICITIES
Ocular toxicities such as conjunctivitis and blepharitis 
with increased lacrimation have been reported for 
both cetuximab and panitumumab47,76. 
Blepharitis, or inflammation of the lid margin, 
results from inflammation of the meibomian glands, 
which contain EGFR-expressing cells. Symptoms 
include itching and watering of the eyes and lids, 
and crusting of the lashes. In general, treatment of 
blepharitis includes warm compresses, eyelid scrubs, 
and topical antibiotic. Eyelid cultures should be 
obtained if the condition fails to improve with these 
measures77. While there are no clear guidelines for 
dose-modifications with EGFR inhibitors, in the case 
of cetuximab, Dranko et al. recommend following 
the dose-modification regimen recommended for 
papulomacular rash (Table 5)77,78.
4.  hYPOMAGnESEMIA
Hypomagnesemia has emerged as a relatively com-
mon side effect of cetuximab and panitumumab 
therapy48,79-84. In the early trials of anti-EGFR 
therapies, the incidence of hypomagnesemia was 
underestimated80,81, likely because these trials fo-
cused on patients with overt hypomagnesemia and 
who therefore had time to develop hypomagnesemia 
during the relatively short treatment intervals85-87. 
However, postmarketing experience with the anti-
EGFR MoAbs began to reveal reports of severe 
hypomagnesemia88, and the incidence was found 
to increase with increasing duration of treatment87. 
In a retrospective review of 114 mCRC patients 
treated with cetuximab at the Roswell Park Cancer 
Center in Buffalo, grade 3–4 hypomagnesemia was 
observed in 5%, 23%, and 47% of patients who 
were treated with cetuximab for less than three 
months, for three to six months, and for more than 
six months, respectively87. 
Panitumumab is associated with a similar risk 
of hypomagnesemia. Among patients with mCRC 
who were treated with panitumumab, with or with-
out best supportive care, magnesium concentrations 
were reduced in 36% of the 231 patients treated with 
panitumumab (3% grade 3–4) compared with 1% 
of those receiving best supportive care alone50. A 
lower frequency of hypomagnesemia was observed 
in the PACCE trial, where the combination of pani-
tumumab, fluorouracil, oxaliplatin, and leucovorin 
in the first-line treatment of mCRC was associated 
with only a 4% incidence of grade 3–4 hypomag-
nesemia34. This low frequency of hypomagnesemia 
has been attributed to a lack of stringent guidelines 
for magnesium monitoring84.
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Severe Acneiform Rash  Cetuximab  Outcome  Cetuximab Dose Modification 
1st  occurrence  Delay infusion 1 to 2 weeks 
Improvement 
No improvement 
Continue at 250 mg/m2  
Discontinue cetuximab 
2nd  occurrence  Delay infusion 1 to 2 weeks 
Improvement 
No improvement 
Reduce dose to 200 mg/m2 
Discontinue cetuximab 
3rd  occurrence  Delay infusion 1 to 2 weeks 
Improvement 
No improvement 
Reduce dose to 150 mg/m2 
Discontinue cetuximab
4th  occurrence  Discontinue ERBITUX S25
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The timing of the onset of hypomagnesemia 
during treatment with anti-EGFR MoAbs can be 
inferred from the rate of magnesium loss and the 
duration of treatment. Among 98 consecutive pa-
tients with mCRC treated with anti-EGFR MoAbs 
in a Belgium study, 97% experienced a progressive 
decrease in serum magnesium concentrations after 
initiation of treatment, with a median time to hypo-
magnesemia of 99 days (range 12–639 days)79. Se-
rum magnesium concentrations returned to normal 
shortly after discontinuation of the EGFR inhibi-
tor79. The slope of the change in serum magnesium 
concentrations from baseline was calculated with 
three early time points and was found to correlate 
well with the slope of the entire dataset, suggesting 
that early characterization of magnesium wasting 
might be possible in clinical practice.
The mechanisms responsible for hypomag-
nesemia in association with anti-EGFR MoAbs have 
not been well defined. Increased EGFR expression in 
the ascending loop of Henle, where 70% of filtered 
magnesium is reabsorbed, may result in damage 
to the renal tubule and interfere with magnesium 
transport85,88. 
Symptoms of hypomagnesemia can be cardio-
vascular, neuromuscular, or behavioral89. Cardiovas-
cular symptoms include ventricular ectopic beats, 
hypertension, enhancement of digoxin-induced 
dysrhythmia, and cardiomyopathies and, in more 
severe cases, ventricular tachycardia, ventricular 
fibrillation, atrial fibrillation, and multifocal atrial 
tachycardia. Neuromuscular and behavioral symp-
toms include weakness, confusion, tetany, agitation, 
tremors and depression and, in more severe cases, 
convulsions, psychosis, ataxia, spasticity, and de-
lirium. Hypocalcemia has been reported in associa-
tion with hypomagnesemia87 and can contribute to 
neuromuscular symptoms. This hypomagnesimic 
hypocalcemia can only be corrected by replacing 
magnesium levels. The pathophysiology of hypocal-
cemia in this setting is related to hypomagnesemia-
induced PTH resistance. 
The impact of hypomagnesemia in patients un-
dergoing anti-EGFR treatment for mCRC has been 
underestimated, most likely because magnesium 
levels are rarely measured during routine screening84. 
Patients’ electrolytes should be periodically moni-
tored during – and for eight weeks after – the comple-
tion of anti-EGFR therapy. Hypomagnesemia should 
be suspected in mCRC patients being treated with 
cetuximab or panitumumab who present with chronic 
diarrhea, hypocalcemia, refractory hypokalemia, and 
ventricular arrhythmia84.
Hypokalemia has similarly been associated with 
anti-EGFR therapy, although to a lesser extent than 
hypomagnesemia. The exact mechanism has not been 
elucidated and it has been observed in the absence of 
diarrhea. Hypokalemia typically responds well to oral 
potassium supplementation.
4.1  Management of hypomagnesemia
Management of hypomagnesemia is dependent on the 
grade of severity outlined in Table 6. Patients with 
grade I hypomagnesemia are generally asymptomatic 
and do not require replacement therapy90. In patients 
with grade 2 hypomagnesemia, oral supplementa-
tion is generally ineffective and poorly tolerated due 
to diarrhea79,87. Weekly intravenous treatment with 
magnesium sulfate 4 g has been shown to be effective 
for patients with magnesium levels of 0.9 to 1.0 mg/
dL (0.37–0.41 mmol/L)90. For patients with grade 2 
hypomagnesemia who are asymptomatic and without 
cardiac risk factors, weekly monitoring without mag-
nesium supplementation may be considered.
Grade 3–4 hypomagnesemia is associated with 
symptoms of fatigue, cramps, and somnolence79, 
which are often attributed to cytotoxic chemotherapy 
and, therefore, go unreported. However, the patient’s 
energy level and performance status may be improved 
by normalizing magnesium levels of those with 
grade 3–4 hypomagnesemia90. Replacement therapy 
is particularly important for these patients, as grade 
3–4 hypomagnesemia puts the patient at increased 
risk for cardiac arrhythmia, which may lead to sud-
den death78.
Management of grade 3–4 hypomagnesemia is 
challenging, requiring intravenous treatment with 
magnesium sulfate 6 to 10 g a minimum of two times 
per week. In severe cases, daily supplementation 
may be necessary, which can be extremely limiting 
and inconvenient for the patient90. In such cases, a 
four-to-eight-week break from EGFR inhibition may 
be considered, as magnesium concentrations return 
to normal approximately four to eight weeks after 
discontinuation. The patient may then be rechallenged 
with the EGFR inhibitor following reversal of the 
hypomagnesemia90.
5.  DIARRhEA
Grade 3–4 diarrhea occurred in up to 2% of patients 
in the EGFR inhibitor monotherapy trials (Tables 1, 
2). The incidence and severity of diarrhea is increased 
when cetuximab or panitumumab is given in combi-
nation with chemotherapy (Table 3), but is generally 
in the range expected for irinotecan therapy. 
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Ta b l e  VI.  Grades of Severity of Hypomagnesemia: National 
Cancer Institute–Common Toxicity Criteria Version 3
Grade 0 Within normal limits
Grade 1 < LLN–1.2 mg/dL or < LLN–0.5 mmol/L
Grade 2 < 1.2–0.9 mg/dL or < 0.5–0.4 mmol/L
Grade 3 < 0.9–0.7 mg/dL or < 0.4–0.3 mmol/L
Grade 4 < 0.7 mg/dL or < 0.3 mmol/L
Abbreviation: LLN = lower limit of normalS26
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Grade 3–4 diarrhea occurred in up to 28% of 
patients in trials combining an EGFR inhibitor with 
chemotherapy (Table 3). In the CRYSTAL trial, 
the rate of grade 3–4 diarrhea was increased by the 
addition of cetuximab to FOLFIRI, compared with 
FOLFIRI alone (15.2% vs. 10.5%)48. In CAIRO233, 
cetuximab increased the rate of grade 1–2 diarrhea, 
but not grade 3–4 diarrhea, when added to a regimen 
of capecitabine, oxaliplatin and bevacizumab. 
The combination of panitumumab and IFL 
(5-fluorouracil [5-FU], leucovorin [LV], and irinote-
can) is not recommended due to the high incidence of 
diarrhea seen in clinical trials. A phase II trial assessed 
the incidence of grade 3–4 diarrhea in mCRC patients 
treated with panitumumab in combination with first-
line irinotecan-containing regimens91. Patients were 
initially treated with panitumumab (2.5 mg/kg weekly 
via a 1-hour infusion) in combination with IFL. How-
ever, the protocol was later amended to substitute 
folinic acid, 5-FU, and irinotecan (FOLFIRI) for 
IFL due to toxicity with IFL. In all, 19 patients were 
treated with IFL and 24 with FOLFIRI in combination 
with panitumumab. Grade 3–4 diarrhea was observed 
in 58% of patients in the IFL group and 25% of pa-
tients in the FOLFIRI group. In the PACCE trial34, 
the addition of panitumumab to either bevacizumab/
irinotecan-based chemotherapy or to bevacizumab/
oxaliplatin-based chemotherapy resulted in an in-
creased incidence of grade 3–4 diarrhea, compared 
with the chemotherapy regimens alone.
Management of diarrhea should be aggressive, 
with treatment including loperamide or diphenoxy-
late92. General management may include bowel rest, 
hydration, and replacement of electrolytes. Hospital-
ization is required for patients with dehydration, fever, 
neutropenia, or nausea and vomiting that prevents 
adequate oral hydration93. 
6.  InfuSIOn REACTIOnS
Severe infusion reactions have been reported in 
approximately 3.5–7.5% of mCRC patients treated 
with cetuximab (Table 1). In randomized trials of 
panitumumab monotherapy in mCRC, infusion-
related reactions of all grade occurred in 0.6–3% of 
patients (Table 2).
A higher incidence of infusion reactions associ-
ated with cetuximab treatment was recently reported 
in a study in Tennessee and North Carolina, which 
included data for 88 patients in clinical trials and 55 
patients outside of trials94. Among those in clinical tri-
als, the grade 3–4 IRs occurred at a rate of 22%. How-
ever, rates of hypersensitivity reactions were much 
lower (< 1%) in most centers in the Northeast.
Most severe (grade 4) infusion reactions with 
cetuximab occur within a few minutes of taking the 
first dose. However, Needle et al. reported that 33% 
of grade 3–4 infusion reactions occurred after the 
second dose; less severe reactions may appear with 
subsequent treatments, suggesting differences in the 
underlying mechanisms responsible for mild and 
severe infusion reactions95.
Severe hypersensitivity reactions to cetuximab 
are thought to be largely due to IgE-mediated ana-
phylaxis, associated with the preexistence of IgE 
antibodies prior to treatment with cetuximab96. Fol-
lowing previous exposure to an antigen, IgE reaginic 
antibodies are released into the circulation by plasma 
cells derived from B lymphocytes under the influence 
of helper T-cells. These antibodies bind to receptors 
on tissue mast cells or blood-borne basophils, thereby 
sensitizing them. Subsequent reexposure to the anti-
gen cross-links the Fab portions of two surface-bound 
IgE molecules, activating the cell and triggering the 
release of chemical mediators. Following reports of 
increased hypersensitivity reactions to cetuximab in 
the southeastern United States, IgE antibodies against 
cetuximab were detected in pretreatment blood 
samples of 68% of patients who had a hypersensitiv-
ity reaction to the drug. In contrast, IgE antibodies 
were detected in only 2% of those without a reaction 
(p < 0.001). The IgE antibody was discovered to be 
specific for the sugar galactose-α-1,3-galactose, ex-
pressed on the Fab portion of the cetuximab heavy 
chain. While the reason for the regional distribution 
of IgE antibodies to galactose-α-1,3-galactose in the 
United States is unclear, tick bites have been proposed 
as a potential etiology96.
The mechanism of panitumumab hypersensitiv-
ity reactions is not clearly understood. In a phase III 
trial of panitumumab monotherapy in patients with 
mCRC, 1.4% of patients tested positive for neutral-
izing antibodies47. However, a correlation between 
neutralizing antibodies and infusion reactions has yet 
to be demonstrated.
Patients may be able to continue treatment with 
an EGFR inhibitor following mild to moderate infu-
sion reactions. Nielsen et al. described two patients 
with grade 2 infusion reactions to cetuximab, who 
were successfully rechallenged with cetuximab under 
controlled conditions97. Prednisone and antihistamines 
were administered prior to treatment, and the cetux-
imab infusion was started on a low rate, with gradual 
titration. The patients showed no evidence of an acute 
reaction during or after the cetuximab infusion and 
were able to continue treatment under the same treat-
ment protocol. More recently, the addition of corti-
costeroids to antihistamines prior to treatment with 
cetuximab has been shown to reduce infusion-related 
reactions, without altering anti-tumor efficacy98.
There are also limited data demonstrating success-
ful treatment with an alternative anti-EGFR MoAb 
following a severe infusion reaction with one anti-
EGFR MoAb. Saif et al. described two mCRC patients 
with severe infusion reactions to panitumumab who 
were successfully challenged with cetuximab99, and 
three patients with severe hypersensitivity reactions 
to cetuximab who were successfully challenged with 
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panitumumab100. The two patients who were switched 
to cetuximab received premedication with prednisone 
and antihistamines, and were treated with cetuximab 
according to a prolonged infusion time and gradual dose 
escalation99. None of the three patients successfully 
switched to panitumumab received pretreatment100.
7.  COnCluSIOnS
The majority of patients treated with an MoAb 
EGFR inhibitor for mCRC will experience derma-
tological side effects, the most common of which 
is the papulopustular skin rash, which occurs early 
during the course of treatment and can impact the 
patient’s quality of life. The severity of the rash is 
dose-dependant and is also correlated with efficacy 
of treatment. Therefore, every effort should be made 
to ensure adherence to therapy. Most cases are mild-
to-moderate in nature and will respond to treatment 
with topical antibiotics. More severe cases may re-
quire the addition of oral antibiotics, along with dose 
reduction or treatment delays. Preemptive treatment 
has been shown to delay the time to skin toxicity. 
Based on two randomized studies, the prophylactic 
use of systemic oral antibiotics, namely doxycycline 
or minocycline, reduces the risk of grade 2 and higher 
skin toxicity. While this practice may eliminate the 
reliability of skin toxicity as a predictive factor of 
response, it does not reduce anti-EGFR efficacy. 
Given the inconvenience associated with severe skin 
toxicities, many practices have moved to prophylac-
tic oral antibiotic administration. 
Other dermatological side effects of both cetux-
imab and panitumumab include xerosis, fissures, hyper-
pigmentation, and changes to the hair and nails. Recent 
reports have also indicated a potential for cetuximab to 
enhance the severity of radiation dermatitis. 
Less common but important side effects include 
diarrhea and infusion reactions. Hypomagnesemia 
has emerged more recently as a side effect of EGFR 
inhibitors and should be considered in patients who 
develop fatigue and muscle weakness on therapy. Se-
rum magnesium levels should be monitored routinely 
in patients undergoing treatment with cetuximab or 
panitumumab for mCRC.
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